- FDA Approved a Neurostimulation Therapy for Major Depressive Disorder
- What is the research progress of immunotherapy for Alzheimer’s disease?
- Protein linked to significantly increased risk of Alzheimer’s disease
- How much do you know about monkeypox?
- COVID-19 linked to dramatic increase in type 1 diabetes in children: up to 72%
- New therapy may conquer cancer with herpes virus
First time: Scientists discovered a second hypoglycemic pathway
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
First time: Scientists discovered a second hypoglycemic pathway.
“Cell Metabolism”: Major progress in diabetes research! One hundred years after the birth of insulin, scientists have discovered a second hypoglycemic pathway for the first time, which will help new treatments for diabetes
When it comes to diabetes, the word “insulin” pops up in my mind.
In 1921, the scientist Frederick Banting (Frederick Banting) teamed up with John Macleod (John Macleod) to successfully extract insulin for the first time.
In 1922, insulin was put into clinical practice and changed the fate of many diabetics. From then on, the words “insulin” and “diabetes” were inseparable.
Until today, insulin is still the only hormone that has been discovered in the body for 100 years to inhibit lipolysis and lower blood sugar.
By activating phosphodiesterase 3B (PDE3B), insulin can inhibit lipolysis to limit hepatic glucose (HGP) production, thereby lowering blood glucose levels .
However, a bug in the human body, insulin resistance, has caused headaches for doctors and scientists. In people with insulin resistance, such as those with type 2 diabetes, insulin is not effective at inhibiting lipolysis.
Once lipolysis is out of control, it will lead to abnormal accumulation of free fatty acids (FFAs) in metabolic tissues such as liver, muscle, and pancreatic islets, causing or aggravating the symptoms of hyperglycemia .
At the beginning of 2022, just a few days ago, an article published in “Cell Metabolism” broke the situation of insulin “together and defeat” in the field of diabetes treatment .
Ronald M. Evans and colleagues from the Salk Institute have identified another hormone that rapidly lowers blood sugar, fibroblast growth factor 1 (FGF1), in adipose tissue .
Like insulin, FGF1 lowers blood sugar levels by inhibiting lipolysis. However, the point is that FGF1 regulates lipolysis by activating phosphodiesterase 4 (PDE4), a novel mechanism independent of insulin .
This means that the FGF1/PDE4 pathway may provide new therapeutic strategies for people with diabetes and insulin resistance .
In fact, as early as 2014, a paper published in the journal “Nature” proposed that FGF1 can act as an effective insulin sensitizer to relieve the symptoms of insulin resistance .
Ronald M. Evans et al. injected FGF1 into peripheral blood and successfully normalized the blood glucose level of diabetic mice in a short time without the risk of hypoglycemia .
Later, Michael Schwartz and others injected FGF1 into the ventricle of diabetic mice, and the mice were in long-term remission . The research results were published in the journal “Nature Medicine” in 2016 .
In this way, FGF1 may have become a new weapon against diabetes .
Comparison of the characteristics of intraventricular injection vs peripheral injection of FGF1
So what is there for scientists to be unsatisfied with? Although it is known that FGF1 effectively lowers glucose in a manner dependent on FGF receptor 1 (FGFR1), its specific mechanism still remains unresolved .
In the process of excavating the hypoglycemic mechanism of FGF1, Evans and his colleagues actually dug up a treasure!
First, the researchers confirmed once again that FGF1 has the effect of lowering blood sugar and is dependent on the expression of FGFR1 in adipose tissue .
They constructed a mouse model (adR1KO) that specifically deleted FGFR1 in mature adipocytes, and injected FGF1 into adR1KO mice and wild-type mice, respectively.
It was found that blood glucose levels were reduced in wild-type mice, but not improved in adR1KO mice.
Subsequently, a series of research results showed that FGF1’s hypoglycemic routine is exactly the same as that of insulin – firstly, it inhibits lipolysis, thereby reducing the concentration of free fatty acids in serum, to limit the production of HGP, and finally to lower blood sugar levels.
A: FGF1 hypoglycemic depends on its receptor FGFR1; B: Inhibits lipolysis; C: Reduces serum FFA concentration; D: Restricts HGP production
So here comes the problem. Although the hypoglycemic effect of the two hormones can be said to be CTRL C + CTRL V, at the molecular level, does FGF1 ?
As mentioned at the beginning, after insulin acts on adipocytes, it inhibits lipolysis by activating PDE3B and initiates the hypoglycemic signaling pathway .
So the researchers put PDE3B to the test to see if the two hormones worked the same way in inhibiting fat breakdown .
Who would have thought that the hypoglycemic mechanisms of FGF1 and insulin diverged here.
In vitro, when the expression of PDE3B was inhibited in the 3T3-L1 adipocyte line, the effect of FGF1 on inhibiting lipolysis was not affected .
In contrast, the inhibitory effect of FGF1 on lipolysis was blocked when PED4 expression was inhibited in either the 3T3-L1 adipocyte line or in mouse or human adipose tissue .
The results of in vivo experiments are also consistent with this. The researchers first gave mice a PDE4 inhibitor, and then injected FGF1 an hour later. Analysis of adipose tissue in these mice showed that FGF1’s ability to inhibit lipolysis was suppressed.
The results of in vitro and in vivo experiments show that when the expression of PDE4 is inhibited, FGF1 fails.
Further studies showed that FGF1 acts on FGFR1 in adipocytes to activate PDE4 through the PI3K pathway, and the activated PDE4 inhibits lipolysis through the cAMP/PKA pathway. Among the several isoforms of PDE4, PDE4D3 is the most effective isoform for inhibiting lipolysis .
That is to say, FGF1 and insulin have taken two distinct paths, respectively, the FGF1/PDE4 and insulin/PDE3B pathways, but the end points of their paths are the inhibition of lipolysis and hypoglycemia.
This caught the eye of Evans and his colleagues .
For a long time, FGF1 has been used as an insulin sensitizer , which can enhance insulin sensitivity in the human body and promote the full utilization of insulin. However, the emergence of the FGF1/PDE4 pathway means that in the hypoglycemic pathway, FGF1 and insulin are not “in series” but “in parallel” .
To further confirm this conclusion, the researchers found insulin-resistant obese mice (C57/B6, obtained on a high-fat diet) .
A large number of previous studies have shown that FGF1 can act as an insulin sensitizer and effectively reduce blood sugar in insulin-resistant obese mice .
This time, however, when these mice were given a PDE4 inhibitor , it was found that the mice’s blood sugar, serum free fatty acids, and insulin levels all experienced transient and significant increases
. Even if FGF1 is injected in vitro, it is unable to recover, and FGF1 loses the ability to lower blood sugar .
A, B: After taking the PDE4 inhibitor, the blood sugar and FFA levels of the mice increased; C: FGF1 did not work either
In addition, Evans and colleagues gave insulin-resistant obese mice a PDE3B inhibitor and found that inhibiting PDE3B expression did not affect FGF1’s ability to regulate blood sugar levels.
It can be concluded that, although from the effect point of view, both FGF1 and insulin can reduce blood sugar by inhibiting lipolysis → limiting HGP production. But at the molecular level, FGF1 and insulin inhibit lipolysis through two independent pathways and initiate a hypoglycemic signaling pathway .
For insulin-resistant mice, FGF1 and insulin are not “promoting” but “complementary”.
Subsequently, the researchers refined the mechanism by which the FGF1/PDE4 pathway regulates lipolysis.
The results showed that the specific phosphorylation of the S44 site is required for the regulation of lipolysis by the FGF1/PDE4 pathway.
FGF1 and insulin hypoglycemic pathways belong to a parallel relationship
Overall, insulin has long been the only known hormone in the body that inhibits fat breakdown and lowers blood sugar.
Although FGF1, which is present in human adipose tissue, has long been shown to have a similar effect to insulin, this time Evans and his colleagues found that FGF1 inhibits lipolysis in an insulin-independent mechanism !
After acting on FGFR1 on adipocytes, FGF1 activates PDE4 to regulate lipolysis, which is independent of the insulin/PDE3B pathway .
After inhibiting lipolysis, free fatty acid levels in serum decrease, limiting hepatic glucose production, which in turn lowers blood glucose levels.
The researchers said that the mechanisms of insulin and FGF1 inhibiting lipolysis and lowering blood sugar can be regarded as two “parallel pathways” . ” When insulin resistance occurs, the insulin signaling pathway is impaired. However, even if the insulin signaling pathway is shut down, the FGF1 signaling pathway can still function . This way lipolysis and blood sugar lowering can still be effectively regulated,” said Gencer Sancar, one of the authors of the paper. .
The discovery of the FGF1/PDE4 pathway may open up a new direction for the study of hyperglycemia and insulin resistance. How to improve the activity of PDE4 also needs to be further explored.
Kitamura, T., et al. (1999). Insulininduced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell. Biol. 19, 6286–6296.
 Saponaro, C., Gaggini, M., Carli, F., and Gastaldelli, A. (2015). The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis. Nutrients 7, 9453–9474.
 Sancar G, et al. FGF1 and insulin control lipolysis by convergent pathways. Cell Metab. 2022 Jan 4;34(1):171-183.e6. doi: 10.1016/j.cmet.2021.12.004. PMID: 34986332.
Suh JM, Jonker JW, Ahmadian M, et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer[J]. Nature, 2014, 513(7518): 436-439.
Gregory J Morton, Michael W Schwartz, et al. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. nm.4101.
First time: Scientists discovered a second hypoglycemic pathway
(source:internet, reference only)